Licensing and Regulatory
To prevent individuals from using pets to obtain pain medications to feed their opioid addiction, New Jersey is implementing stricter guidelines for reporting prescription information for animals.
The FDA alerts veterinarians and veterinary pharmacologists that the strength of epinephrine might be expressed differently on the labeling on certain human and animal epinephrine products. To avoid dosing errors in animals, the FDA recommends that veterinarians carefully review an epinephrine product’s labeling before administering the drug to determine if strength is expressed as mg/mL or as a ratio. The FDA also recommends that veterinary emergency dosage charts include epinephrine products that are labeled both ways (mg/mL and ratio) to reduce confusion and potential dosing errors.
All applicable provisions of KRS Chapter 218A, 902 KAR Chapter 55 and other licensure board regulations will apply to gabapentin.
The scourge of opioid addiction has received considerable attention for some time, and now legislation is proposed to address the overuse of addictive prescription opioids: Senate bill 892, the Opioid Addiction Prevention Act of 2017. The proposed legislation defines conditions of acute pain and tells physicians how they may prescribe for them.
Need Regulatory Assistance
If you need help with regulatory or licensing issues, we're happy to help. We have a wide variety of resources to help you when issues arise.
Are you looking for a place to let your talents Schein? At Henry Schein Animal Health, we help our practitioner customers better serve their patients and take pride in providing the best customer experience possible. Search our open positions to see our available opportunities.
Stay current with what’s going on with Henry Schein Animal Health, subscribe to receive our newsletter and email communications. Subscribers will receive the latest information in practice management, sales and marketing, animal health, and more.